Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Zachary BessettenccRCC | February 21, 2024
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Read More
Katy MarshallAdvanced Renal Cell Carcinoma | February 21, 2024
Researchers analyzed the data from patients who received anti–LAG-3 and anti–PD-1.
Emily MenendezLocalized Renal Cell Carcinoma | February 15, 2024
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | February 15, 2024
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | February 15, 2024
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Thomas Powles, MBBS, MRCP, MDAdvanced Renal Cell Carcinoma | February 13, 2024
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their excitement for the road ahead in kidney cancer.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
Brad McGregor, MDRenal Cell Carcinoma | February 10, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Emily MenendezProstate Cancer | February 12, 2024
The quality of patient-reported outcome analyses over the past 15 years is unknown, as reporting has waned.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
Advertisement
Advertisement
Advertisement